Contrast-Enhanced Ultrasound for Soft Tissue Sarcoma

This trial explores a new method of using ultrasound imaging to plan and predict responses to radiation therapy (RT) for soft tissue sarcoma, a cancer that begins in tissues like muscle or fat. The researchers will employ a special ultrasound technique called contrast-enhanced ultrasound (CEUS) with Definity, a contrast agent, to determine if it provides better images of the tumor's blood flow and pressure. This could help doctors assess how well the tumor responds to treatment. Individuals with confirmed soft tissue sarcoma in the trunk or limbs, scheduled to receive RT before surgery, might be suitable for this study. As an Early Phase 1 trial, this research aims to understand how the ultrasound technique functions in people, offering participants a chance to contribute to groundbreaking advancements in cancer treatment.

The trial information does not specify whether you need to stop taking your current medications. It's best to discuss this with the trial coordinators or your doctor.

Research has shown that Definity, the ultrasound contrast agent used in this study, is generally safe for many people. Patients with heart and lung conditions have used it without major problems. However, reports of serious heart and lung reactions exist, so awareness of these risks is important. Those allergic to any ingredients in Definity should not use it. Discuss all health conditions with a doctor before joining any trial.¹²³⁴⁵

Researchers are excited about the use of Contrast-Enhanced Ultrasound (CEUS) with Definity for soft tissue sarcoma because it offers a non-invasive way to visualize tumors more clearly than traditional imaging methods. Unlike standard care options like MRI or CT scans, this technique uses ultrasound enhanced with a contrast agent, providing real-time imaging that helps in better understanding the tumor's blood supply and structure. This could potentially lead to more precise treatment planning and monitoring, offering a unique advantage over existing imaging techniques.

Research has shown that contrast-enhanced ultrasound (CEUS) with Definity, which participants in this trial will receive, can help evaluate soft tissue sarcomas. CEUS enhances imaging accuracy by highlighting blood flow and tissue differences, aiding doctors in assessing tumor response to treatment. Studies have found that CEUS can match MRI effectiveness in evaluating tumor changes. Definity, the contrast agent used in this trial, clarifies ultrasound images, revealing tumor behavior. This makes it a potentially useful tool for planning and monitoring the effectiveness of radiation therapy.⁶⁷⁸⁹¹⁰